Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Asep Medical Holdings Inc C.ASEP

Alternate Symbol(s):  SEPSF

ASEP Medical Holdings Inc. is a Canada-based company, which is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. The Company’s consolidates three development-stage companies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. It provides medical devices with an anti-microbial, antifouling coating through its SafeCoat Medical Inc. The Company provides diagnostic kits for predicting the onset of severe Sepsis and organ failure through its Sepset Biosciences Inc. The Company also offers peptide technology through its ABT Innovations Inc. and covers a range of therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. SafeCoat Medical Inc.'s technology incorporates self-assembling biocompatible polymers combined with conjugated antimicrobial peptides.


CSE:ASEP - Post by User

Post by Justdosomeddon Jun 15, 2022 2:33pm
128 Views
Post# 34758934

Continued Development + European Patent

Continued Development + European Patent
According to the CDC, each year around 1.7M adults develop sepsis of which nearly 270,000 die as a result in the US alone. But what is sepsis and why is it so deadly? Sepsis is when the body has an extreme response to an infection which damages the body’s own tissue and functionality. Due to its unique nature, sepsis is treatable if it is identified and treated quickly. But current methods often take 12+ hours to test and diagnose a patient for sepsis which then they have a 22% mortality rate due to the extended time waiting for diagnosis without treatment. That's where $ASEP.C comes in. Their novel diagnosis allows patients to be tested for sepsis within an hour to save the much-needed time for treatment. And they’ve already conducted a clinical study which has proven the effectiveness of their new method.
 
Furthermore, $ASEP.C isn't just focusing on the diagnosis side, they're also developing a pharmaceutical peptide to help combat antibiotic-resistant biofilms. Current study results show promise with the peptide, and they're pursuing clinical validation in treating organisms associated with Sinusitis pathogens in a planned study in Vancouver.
 
$ASEP.C’s approach to both the treatment and diagnosis of currently underserved health issues is what sets them apart. Their extensive net of patents, IP, and funding from top institutions shows that they're getting closer and closer to regulatory approval, development, and revenue generation. Plus, a recent patent was granted in Europe which continues to open the door for a more global audience/potential markets for the sepsis diagnosis technology).
 
Overall, considering the $17M valuation and the huge amount of lives their technology can save, there's significant upside here as they continue to test, research, and close in on approval.
<< Previous
Bullboard Posts
Next >>